R&D channel feed – Endpoints News

R&D channel feed

Merck beat Bellus, but their full cough data aren't earning much enthusiasm

5 years ago

After carefully building up expectations, a small-cap biotech’s big plans come crashing down in PhIII catastrophe

5 years ago

Grifols makes a $146M bet on a Stanford play in a controversial anti-aging field

5 years ago

Roche nabs an FDA OK for Gavreto, triggering a heavyweight bout with rivals at Eli Lilly

5 years ago

Roche to read out even more data on megablockbuster Ocrevus in MS

5 years ago

Vertex and Covid-19 spell the end for Savara's CF program

5 years ago

China biotech InxMed bags $19M Series A+ to develop PhI FAK inhibitor

5 years ago

Akebia shares MACEd as their PhIII anemia drug fails on safety, offering rival FibroGen a huge advantage

5 years ago

As Covid research heats up, J&J retires a BARDA-funded flu antiviral they worked on for 7 years

5 years ago

Covid-19 roundup: Albert Bourla says Pfizer PhIII is at 23,000 patients, submission coming end of October

5 years ago

Coming up behind the mRNA leaders, Sanofi, GSK pivot into PhI/II trial for their traditional tech approach to a Covid-19 vaccine. This race isn't over yet

5 years ago

Amylyx spotlights a PhII success in slowing ALS progression. And they’re taking it to the FDA

5 years ago

A pair of Bay Area biotech upstarts with deep pockets and a shared interest in curative cancer drugs join R&D forces

5 years ago

Another Big Pharma 'lifer' in the top ranks of R&D is starting a new chapter in biotech

5 years ago

Wheeling and dealing his way to a cancer drug pipeline, Gilead’s Dan O’Day crafts a rich, $805M deal to bag a preclinical I/O drug

5 years ago

Canadian biotech to discontinue omega-3 program after second PhIII fails on significant triglyceride reduction

5 years ago

Lumen Bioscience reels in $16M Series B to 'democratize' biologics

5 years ago

Sanofi, Regeneron hit final nail on the IL-6 repurposing coffin as Kevzara fails PhIII

5 years ago

Novartis says its Soliris add-on might be able to replace the Alexion drug altogether. But is it too late?

5 years ago

AstraZeneca looks to widen its lead over SGLT2 rivals with another round of landmark data

5 years ago

GSK, Vir barrel into a fast PhII/III for their lead Covid-19 antibody, chasing a moving target with quick OK in sight

5 years ago

New analysis shows inclisiran consistency in LDL-C reduction as Novartis readies for FDA decision

5 years ago

Akcea shows off what Novartis missed and what Pfizer gained, offering more details on PhII cardio data

5 years ago

GlaxoSmithKline says it's one step closer to a functional hep B cure — but J&J and other rivals are rushing there

5 years ago

First page Previous page 190 191 192193194 195 196 Next page Last page